Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.03 (17.647%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

Thu, 18th May 2023 14:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Commences a phase 1a clinical trial for its SDC-1801 treatment. Says patient recruitment is in progress at clinical units in Victoria, Australia. SDC-1801 is a potential therapeutic for a number of autoimmune diseases. Says application trial follows approval by the Human Research Ethics Committee, while the application has also been acknowledged by Australia's Therapeutic Goods Administration. Says phase 1b clinical study expected to begin in psoriasis patients in 2024.

----------

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing - Says study data indicates its NXP002 treatment alone delivers an anti-inflammatory effect, suppressing the release of inflammatory cytokines by over 90%. Adds that the treatment shows an addition anti-inflammatory effect when used with current standards of care. Says results suggest NXP002 increases efficacy of existing therapies with the benefit of inhaled delivery. Says anti-inflammatory takes only an hour to have an effect, and strong effect lasts for 12 hours, and anti-inflammatory effect is still present after 24 hours. "I'm absolutely delighted with the data we've generated over recent months - all the results we've achieved are as good as we could have hoped for and are the first results from advanced 'close to patient' IPF and inflammation human tissue disease models," comments Executive director Dan Gooding.

----------

Conygar Investment Co PLC - London-based property investor and developer - Says Nottingham City Council has approved its application for the next phase of The Island Quarter development. Says application includes 23,123 square metre bioscience building, including laboratory and office space. Chief Executive Robert Ware comments: "We are delighted that the next phase of development has been approved. Nottingham is already home to a large number of exciting businesses in the bioscience space and this scheme will be an excellent addition to the mixed-use development we are creating at The Island Quarter".

----------

Secure Trust Bank PLC - Solihull, England-based savings accounts and lending services provider - Says net lending in the first quarter of 2023 was GBP3.01 billion, up 17% from GBP2.57 billion a year ago. New business lending rose 7.2% to GBP523.5 million, from GBP488.2 million, which it says demonstrates sustained growth momentum, in spite of tightened lending criteria. Adds that its cost optimisation programme is on track to deliver GBP4 million in annualised savings by the end of 2023. "We see significant opportunity for sustainable growth in our focused market segments and are well positioned to help consumers and businesses fulfil their ambitions and to continue to grow our net lending and scale our business as we strengthen our distribution networks and relationships...Although the economic environment remains uncertain, we have started the year positively and are confident in delivering on our plans for the full year and our medium term targets," Chief Executive David McCreadie says.

----------

Artemis Resources Ltd - Perth-based based mining company, with gold, copper and cobalt projects in Australia - Says historical geology and a data review confirms that its 2020 drill programme intercepted gold mineralisation within a quartz diorite intrusion. Says drilling has defined the intrusion over 2 kilometres, with elevated gold in rock chips over a strike length of 4 kilometres. Says there may be a possible relationship with Sanukitoid granitoids identified by De Grey Mining in the Mallina basin. Adds that an induced polarisation survey will begin in May, in order to help identify sulphides at depth. Exploration Manager Luke Meter says: "We have a new understanding of the importance of intrusion related gold in the Pilbara, including the identification of Sanukitoid like intrusions by the GSWA in the vicinity of the Karratha Granodiorite, some 2.5 km from Lulu Creek. The significance of the historic gold mineralisation therefore becomes apparent. With the Lulu Creek reconnaissance drill holes displaying similar grade and scale to De Grey's Diucon deposits, the potential upside for Lulu Creek is appreciable."

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Oct 2019 12:27

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Read more
10 Sep 2019 13:47

Nuformix Chief Financial Officer Kirk Siderman-Wolter Resigns Abruptly

(Alliance News) - Pharmaceutical company Nuformix PLC on Tuesday said Chief Financial Officer and Senior Independent Non-Executive Director Kirk Siderman-Wolter has resigned with immediate company

Read more
9 Sep 2019 11:25

Nuformix, Ebers Tech File Patent For Cannabinoid Cocrystals

(Alliance News) - Pharmaceutical company Nuformix PLC on Monday said it and partner Ebers Tech Inc have filed the first patent in relation to cannabinoid cocrystals.The patented cannabinoid

Read more
6 Sep 2019 12:17

Nuformix Hires Cambridge Interstitial Lung Disease Unit Lead Clinician

(Alliance News) - Nuformix PLC said on Friday it has appointed Muhunthan Thillai to its scientific advisory board with immediate effect.Thillai is the lead clinician for the Cambridge Lung

Read more
18 Jul 2019 11:16

Nuformix Annual Loss Narrows As Revenue Jumps On NXP001 Progress

(Alliance News) - Nuformix PLC on Thursday said its revenue multiplied in its most recently-ended financial year as it has secured its first licensing income from NXP001.NXP001 is one of in

Read more
30 May 2019 10:33

WINNERS & LOSERS SUMMARY: De La Rue Down As CEO Exits And Profit Falls

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - LOSERS----------National a

Read more
30 May 2019 10:14

Nuformix Shares Jump On Positive NXP001 Clinical Study Results

LONDON (Alliance News) - Shares in Nuformix PLC surged on Thursday as the company reported positive results in its clinical study of NXP001.Nuformix shares were trading 30% higher at 13.50

Read more
9 Apr 2019 11:25

Nuformix inks cannabinoid therapeutics deal with Ebers Tech

(Sharecast News) - Pharmaceutical development company Nuformix has inked an agreement for cannabinoid therapeutics development, licensing and commercialisation with Canadian outfit Ebers Tech.

Read more
9 Apr 2019 10:46

WINNERS & LOSERS SUMMARY: 7digital Warns Of Need For Capital Raise

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Anglo up -

Read more
22 Mar 2019 08:50

Nuformix Doses First Patient In NXP001 Anti-Nausea Drug Trial

LONDON (Alliance News) - Nuformix PLC on Friday said it has begun clinical studies for its anti-nausea drug NXP001 and dosed its first patient.Shares in Nuformix were down 4.6% at 2.10 on a

Read more
27 Feb 2019 10:48

MHRA gives go-ahead to Nuformix for human studies

(Sharecast News) - Pharmaceutical development company Nuformix has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin human pharmacokinetics studies for its lead asset, NXP001, it announced on Wednesday.

Read more
3 Dec 2018 09:53

Nuformix Reports Positive Results From NXP002 Pre-Clinical Trial

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC on Monday reported positive results from its completed NXP002 fibrosis programme pre-clinical trial for the treatment of a of

Read more
27 Nov 2018 10:04

Nuformix Expands NXP001 Agreement With Additional Pre-Clinical Study

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC said on Tuesday it has expanded its current licensing agreement with partner Newsummit Biopharma for the development of cancer

Read more
14 Sep 2018 10:17

Nuformix Rises As NXP001 Passes "Major" Pre-Clinical Milestone

LONDON (Alliance News) - Shares in pharmaceutical firm Nuformix PLC rose Friday it has received a GBP500,000 payment after its NXP001 product reached a pre-clinical milestone.Nuformix was a

Read more
12 Sep 2018 16:00

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 SeptemberBahamas PetroleumFlybe GroupBetter Capital PCCWorldwide 14 UK 17

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.